SRPT Sarepta Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SRPT

Price (delayed)

$16.07

Market cap

$1.72B

P/E Ratio

229.57

Dividend/share

N/A

EPS

$0.07

Enterprise value

$2.3B

?
Relative Growth: Rel. Growth: 45
Relative Strength: Rel. Strength: 37
Relative Valuation: Rel. Valuation: 42
Relative Profitability: Rel. Profitability: 49

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and ...

Highlights
The EPS has soared by 144% from the previous quarter and by 105% YoY
The net income has soared by 110% YoY
Sarepta Therapeutics's quick ratio has increased by 41% YoY but it has decreased by 18% from the previous quarter
SRPT's gross profit is down by 40% year-on-year and by 4.8% since the previous quarter
Sarepta Therapeutics's gross margin has decreased by 26% YoY and by 3.9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sarepta.com
Peers: GILD NVAX PTCT BCRX

Key stats

What are the main financial stats of SRPT

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
0.37%
1 week
-9.82%
1 month
-2.67%
1 year
-9.82%
YTD
-25.33%
QTD
-11.8%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$1.96B
Gross profit
$1.11B
Operating income
-$48.9M
Net income
$14.76M
Gross margin
56.8%
Net margin
0.8%
SRPT's net margin has surged by 114% year-on-year
The net income has soared by 110% YoY
SRPT's operating margin has soared by 66% from the previous quarter and by 52% YoY
SRPT's operating income has soared by 66% since the previous quarter and by 61% year-on-year

Price vs fundamentals

How does SRPT's price correlate with its fundamentals

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
SRPT P/E details
P/E
229.57
P/B
1.11
P/S
0.87
EV/EBIT
61.65
EV/EBITDA
28.18
EV/Sales
1.18
The EPS has soared by 144% from the previous quarter and by 105% YoY
SRPT's P/B is 88% below its 5-year quarterly average of 9.6 and 26% below its last 4 quarters average of 1.5
The company's equity rose by 16% YoY
The P/S is 87% less than the 5-year quarterly average of 6.5 and 13% less than the last 4 quarters average of 1.0
The revenue fell by 19% YoY

Efficiency

How efficient is Sarepta Therapeutics business performance
The ROS has soared by 137% YoY
Sarepta Therapeutics's ROIC has soared by 134% YoY
The ROA has soared by 113% YoY
The return on equity has surged by 109% year-on-year

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 93% more than the total liabilities
Sarepta Therapeutics's quick ratio has increased by 41% YoY but it has decreased by 18% from the previous quarter
SRPT's total liabilities is down by 25% YoY
SRPT's debt is 31% smaller than its equity
The debt to equity has declined by 27% year-on-year
SRPT's debt is down by 16% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.